Japanese immunology, biochemistry, and health-tech pioneer, Cellspect is developing breakthrough highly portable point-of-care-testing (POCT) devices that can address the needs of dispersed populations.

Their innovative POCT solutions are ushering in a new era of simple, fast, and accurate blood testing which can be easily done by the patient themselves, at home, work, or elsewhere.  Cellspect has also miniaturized conventional POCT into a smart-device driven platform that enables detection using mobile apps, that can detect multiple bio-parameters, simultaneously, from very limited samples, such as a single drop of blood.  These innovative tools are enabling anyone to easily self-monitor, addressing the challenge of empowering anyone, anywhere to access their state of health freely.

Current biochemical tests include sugar metabolism, lipid, and COVID-19 antigen, and more tests for cardiovascular diseases and infectious diseases will be released in the near future, bringing true self-testing to a new digital age.

Through providing tools that allow anyone to easily self-monitor, Cellspect addresses the challenge of enabling anyone, anywhere to access their state of health freely.

In 2019, Jameel Health began a collaboration with Cellspect to make these innovative products available across the Middle East, Africa, Türkiye, South and Southeast Asia. 

Visit: Cellspect